Trial Profile
A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Ixabepilone (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 May 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 30 May 2012 Actual patients number is 19 as reported by ClinicalTrials.gov.